Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis

Clinical Infectious Diseases

Volumn 30, Issue 5, 2000, Pages 779-783

  Narita, Masahiro ^a,b,c   Stambaugh, Jerry J ^a   Hollender, Elena S ^a   Jones, Denis ^d   Pitchenik, Arthur E ^c,e   Ashkin, David ^b,c,d,e  

^a A G Holley State Tuberculosis Hospital   (United States)

^b FLORIDA DEPARTMENT OF HEALTH   (United States)

^c Division of Pulmonary and Critical Care Medicine   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RIFABUTIN;

ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIBIOTICS, ANTITUBERCULAR; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMAN; MALE; MIDDLE AGE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RIFABUTIN; TUBERCULOSIS, PULMONARY;

EID: 0033797005     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313771     Document Type: Article

References (21)

1. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
2. Tuberculosis in patients with human immunodeficiency virus infection
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
5. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
6. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
7. Clinical update: Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin
8. Patient compliance and drug failure in protease inhibitor monotherapy
9. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: A multinational, randomized, comparative study versus rifampicin
10. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis
11. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis: A single blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis
12. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects
13. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin
14. Indinavir (MK 639) drug interaction studies
15. Strategic approach to nelfinavir mesylate drug interactions involving CYP3A metabolism
16. Use of rifabutin with protease inhibitors for HIV-infected TB patients
17. Using therapeutic drug monitoring to dose the antimycobacterial drugs
18. Clinical Update: Impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin
19. Effect of Mycobacterium tuberculosis on HIV replication: Role of immune activation
20. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
21. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy